604
Participants
Start Date
September 7, 2023
Primary Completion Date
April 30, 2026
Study Completion Date
April 30, 2027
RMC-9805
Oral Tablets
RMC-6236
Oral Tablets
RECRUITING
NYU Langone, New York
RECRUITING
Memorial Sloan Kettering Cancer Center, New York
RECRUITING
Johns Hopkins University, Baltimore
RECRUITING
NEXT Oncology Virginia, Fairfax
RECRUITING
Duke Cancer Center, Durham
RECRUITING
Carolina BioOncology Institute, Huntersville
RECRUITING
Lee Moffitt Cancer Center, Tampa
RECRUITING
Florida Cancer Specialists, Sarasota
RECRUITING
Sarah Cannon Research Institute, Nashville
RECRUITING
The Christ Hospital, Cincinnati
RECRUITING
Sarah Cannon Research Institute at Mary Crowley, Dallas
RECRUITING
University of Texas, MD Anderson Cancer Center, Houston
RECRUITING
START, San Antonio
RECRUITING
University of California, Davis Comprehensive Cancer Center, Sacramento
RECRUITING
Smilow Cancer Hospital (Yale University), New Haven
RECRUITING
Massachusetts General Hospital, Boston
RECRUITING
Dana-Farber Cancer Institute, Boston
Revolution Medicines, Inc.
INDUSTRY